The Goal of this study is to evaluate the safety, tolerability, and clinical responses following single dose of DSP-3077. Study enrolls both male and female patients in 3 cohorts with each cohort defined by visual acuity (VA) criteria and dose level of DSP-3077. Each cohort will include 4 participants.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of ocular adverse events (AEs)
Timeframe: 60 months
Incidence of ocular serious adverse events (SAEs)
Timeframe: 60 months
Incidence of ocular adverse events (AEs) leading to discontinuation
Timeframe: 60 months
Incidence of adverse events (AEs)
Timeframe: 60 months
Incidence of serious adverse events (SAEs)
Timeframe: 60 months
Incidence of adverse events (AEs) leading to discontinuation
Timeframe: 60 months
Incidence of adverse events (AEs) leading to death
Timeframe: 60 months